Conference
Outcomes in Relapsed/Refractory Burkitt Lymphoma: A Multi-Centre Canadian Experience
Abstract
Introduction: Burkitt lymphoma (BL) is an aggressive B cell lymphoma with a distinct morphology, immunophenotype and characteristic C-MYC gene rearrangement. When treated with intensive chemotherapy, outcomes are excellent with a reported overall survival of greater than 80% at 3 years. A small subset of patients have primary refractory or relapsed disease, but there have been few reports of treatment and outcomes of these patients due to the …
Authors
Manji F; Chow E; Gerrie AS; Chua N; Puckrin R; Stewart DA; Skrabek P; Bence-Bruckler I; Keating M; Britto J
Volume
138
Pagination
pp. 2525-2525
Publication Date
November 5, 2021
DOI
10.1182/blood-2021-146036
Conference proceedings
Blood
Issue
Supplement 1
ISSN
0006-4971